Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 13/20 | 0.66 |
| ▸ | ATR | Q13535 | 5/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | PRKDC | P78527 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1271439 | 0.83 | MTOR (0.81) | MTORATRPIK3CACYP2C9PIK3CD | |
| SCHEMBL1271831 | 0.82 | MTOR (0.63) | MTORATRPIK3CACYP2C9PIK3CD | |
| SCHEMBL4368023 | 0.81 | MTOR (0.76) | MTORATRPIK3CACYP2C9PIK3CD | |
| SCHEMBL8228636 | 0.80 | MTOR (0.64) | MTORATRPIK3CACYP2C9PIK3CD | |
| SCHEMBL1271420 | 0.80 | MTOR (1.00) | MTORATRPIK3CACYP2C9PIK3CD | |
| SCHEMBL4530579 | 0.80 | MTOR (1.00) | MTORATRPIK3CACYP2C9PIK3CD | |
| SCHEMBL1271359 | 0.79 | MTOR (0.81) | MTORATRPIK3CACYP2C9PIK3CD | |
| SCHEMBL4523291 | 0.79 | MTOR (0.86) | MTORATRPIK3CACYP2C9PIK3CD | |
| SCHEMBL1271532 | 0.79 | MTOR (0.79) | MTORATRPIK3CACYP2C9PIK3CD | |
| SCHEMBL3605023 | 0.78 | MTOR (0.78) | MTORATRPIK3CACYP2C9PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007080382-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | WO | disclosed |